• Eline L Giraud, Kaylee R M Ferrier, LankheetNienke A GNAGDepartment of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, Netherlands., Ingrid M E Desar, Neeltje Steeghs, Rypko J Beukema, Nielka P van Erp, and Elise J Smolders.
• Department of Clinical Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
• Lancet Oncol. 2022 Sep 1; 23 (9): e406e415e406-e415.

AbstractPatients with cancer are prone to prolongation of the corrected QT interval (QTc) due to the use of anticancer drugs with QTc-prolonging potential in combination with electrolyte imbalances caused by, for example, gastrointestinal side-effects. However, most anticancer drugs were approved with little information on their QTc-prolonging potential and the added risk of torsade de pointes. The absence of this information on the drug label poses a considerable challenge to clinicians regarding the measures that need to be taken to safely start anticancer treatment. In this Review, we provide a comprehensive overview of the evidence for the QTc-prolonging properties of 205 anticancer drugs and 14 antiemetic drugs available from drug labels, assessment reports, and published studies. We classify the drugs as low-risk, moderate-risk, or high-risk for QTc prolongation. We also discuss the clinical relevance of these findings and include practical recommendations to guide clinicians to select the drugs with the least QTc-prolonging properties and to adequately monitor susceptible patients.Copyright © 2022 Elsevier Ltd. All rights reserved.

11 keywords...

hide…